PRME Stock Overview
A biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Prime Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$9.86 |
| 52 Week Low | US$2.85 |
| Beta | 2.09 |
| 11 Month Change | -20.60% |
| 3 Month Change | -29.05% |
| 1 Year Change | -55.92% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.18% |
Recent News & Updates
Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04
Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Recent updates
Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24Shareholder Returns
| PRME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | 2.5% | 2.2% |
| 1Y | -55.9% | 16.1% | 31.6% |
Return vs Industry: PRME underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: PRME underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| PRME volatility | |
|---|---|
| PRME Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRME's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 234 | Keith Gottesdiener | primemedicine.com |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Prime Medicine, Inc. Fundamentals Summary
| PRME fundamental statistics | |
|---|---|
| Market cap | US$408.31m |
| Earnings (TTM) | -US$219.25m |
| Revenue (TTM) | US$800.00k |
510.4x
P/S Ratio-1.9x
P/E RatioIs PRME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRME income statement (TTM) | |
|---|---|
| Revenue | US$800.00k |
| Cost of Revenue | US$162.64m |
| Gross Profit | -US$161.84m |
| Other Expenses | US$57.41m |
| Earnings | -US$219.25m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | -20,230.50% |
| Net Profit Margin | -27,406.12% |
| Debt/Equity Ratio | 0% |
How did PRME perform over the long term?
See historical performance and comparison